» Articles » PMID: 33648518

Risk for Recurrent Cardiovascular Disease Events Among Patients with Diabetes and Chronic Kidney Disease

Abstract

Background: Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI).

Methods: We compared the risk for recurrent CVD events among US adults with health insurance who were hospitalized for an MI between 2014 and 2017 and had (1) CVD prior to their MI but were free from diabetes or CKD (prior CVD), and those without CVD prior to their MI who had (2) diabetes only, (3) CKD only and (4) both diabetes and CKD. We followed patients from hospital discharge through December 31, 2018 for recurrent CVD events including coronary, stroke, and peripheral artery events.

Results: Among 162,730 patients, 55.2% had prior CVD, and 28.3%, 8.3%, and 8.2% had diabetes only, CKD only, and both diabetes and CKD, respectively. The rate for recurrent CVD events per 1000 person-years was 135 among patients with prior CVD and 110, 124 and 171 among those with diabetes only, CKD only and both diabetes and CKD, respectively. Compared to patients with prior CVD, the multivariable-adjusted hazard ratio for recurrent CVD events was 0.92 (95%CI 0.90-0.95), 0.89 (95%CI: 0.85-0.93), and 1.18 (95%CI: 1.14-1.22) among those with diabetes only, CKD only, and both diabetes and CKD, respectively.

Conclusion: Following MI, adults with both diabetes and CKD had a higher risk for recurrent CVD events compared to those with prior CVD without diabetes or CKD.

Citing Articles

Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.

Su H, Yang C, Lee Y, Su P, Liu Y, Ou H JAMA Netw Open. 2024; 7(10):e2441765.

PMID: 39476235 PMC: 11525605. DOI: 10.1001/jamanetworkopen.2024.41765.


Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial.

You S, Chen H, Miao M, Du J, Che B, Xu T Cardiovasc Diabetol. 2023; 22(1):274.

PMID: 37817149 PMC: 10566135. DOI: 10.1186/s12933-023-01996-0.


Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study.

Ramezankhani A, Azizi F, Hadaegh F Cardiovasc Diabetol. 2023; 22(1):270.

PMID: 37794456 PMC: 10552420. DOI: 10.1186/s12933-023-02008-x.


Ambulatory Blood Pressure Monitoring as a Useful Tool in the Cardiological Assessment of Pancreas Transplant Recipients with Type 1 Diabetes.

Buksinska-Lisik M, Kwasiborski P, Ryczek R, Lisik W, Mamcarz A Diagnostics (Basel). 2023; 13(17).

PMID: 37685261 PMC: 10487007. DOI: 10.3390/diagnostics13172724.


Health-related patterns and chronic kidney disease in the Brazilian population: National Health Survey, 2019.

de Sousa L, Silva N, Azeredo C, Rinaldi A, Saraiva da Silva L Front Public Health. 2023; 11:1090196.

PMID: 37089474 PMC: 10117670. DOI: 10.3389/fpubh.2023.1090196.


References
1.
Brieger D, Pocock S, Blankenberg S, Chen J, Cohen M, Granger C . Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. Int J Cardiol. 2020; 311:7-14. DOI: 10.1016/j.ijcard.2020.01.070. View

2.
Hasin T, Hochadel M, Gitt A, Behar S, Bueno H, Hasin Y . Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus. Am J Cardiol. 2009; 103(6):772-8. DOI: 10.1016/j.amjcard.2008.11.034. View

3.
Kent S, Safford M, Zhao H, Levitan E, Curtis J, Kilpatrick R . Optimal use of available claims to identify a Medicare population free of coronary heart disease. Am J Epidemiol. 2015; 182(9):808-19. PMC: 4617296. DOI: 10.1093/aje/kwv116. View

4.
Kumamaru H, Judd S, Curtis J, Ramachandran R, Hardy N, Rhodes J . Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014; 7(4):611-9. PMC: 4109622. DOI: 10.1161/CIRCOUTCOMES.113.000743. View

5.
McMurray J, Wheeler D, Stefansson B, Jongs N, Postmus D, Correa-Rotter R . Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation. 2020; 143(5):438-448. DOI: 10.1161/CIRCULATIONAHA.120.051675. View